FREE Case Evaluation: 1-800-375-6160
As of August 2024, retired Judge Lawrence F. Stengel was appointed as the Special Discovery Master to oversee discovery disputes between the parties and third parties involved in the case.
In mid-August, the court issued Case Management Order No. 17, outlining the fee structure for the Ozempic MDL. A 9% fee from any gross monetary recovery, whether from settlement, judgment, or other forms of relief, will be allocated to the GLP-1 Fee Fund to compensate attorneys for their work benefiting all plaintiffs in the MDL.
Additionally, 2% of the gross recovery will go to the GLP-1 Expense Fund, covering litigation expenses such as discovery and expert analysis.
In an MDL, these fees are designed to distribute the costs of litigation fairly among all plaintiffs. Typically, the 2% expense fee impacts plaintiffs directly, while the 9% attorneys' fee is usually deducted from the contingency fees paid to plaintiffs’ lawyers.
In early August, a new lawsuit was filed in the MDL by a New Hampshire resident who used Ozempic from June 2022 to September 2023 and subsequently developed gastroparesis, a condition that paralyzes the stomach muscles, leading to severe digestive issues. The plaintiff claims that Novo Nordisk failed to adequately warn about the risks associated with Ozempic, resulting in her injuries and emotional distress.
Looking ahead, Judge Karen Spencer Marston has scheduled a "Science Day" for September 4, 2024. This unique proceeding will allow both parties to present an objective overview of the relevant medical and scientific issues related to GLP-1 RAs, helping the court better understand the science behind the claims. The presentations will focus strictly on scientific information, excluding individual cases or marketing practices, and are intended to be non-discoverable to encourage open discussion.
In the broader context of the MDL, the number of active cases has surged. From July to August 2024, the case count in MDL-3094, which includes various GLP-1 products like Ozempic, increased dramatically from 111 to 346—an over 200% jump in just one month.
A status conference was also held on August 8, 2024, where likely key issues were discussed, including the progress of electronic Plaintiff Fact Sheets (e-PFS), ongoing discovery developments, updates on stayed cases, and logistical planning for the upcoming Science Day.
The next status conference is scheduled for January 2025.
Ozempic (semaglutide) is used to manage type 2 diabetes and treat obesity. However, it has been associated with serious gastrointestinal issues. Studies and reports have linked prescribed Ozempic to conditions such as gastroparesis (stomach paralysis), causing significant digestive discomfort and complications.
Known Injuries and Side Effects
Ozempic can have a range of side effects, including:
These side effects highlight the importance of being informed about the potential risks associated with Ozempic use.
The primary factor determining eligibility revolves around the medical evidence linking Ozempic consumption to the development of specific health issues. Plaintiffs need to provide medical documentation to substantiate their claims that their health conditions are directly linked to their use of Ozempic.
Another critical aspect of eligibility is the duration and dosage of Ozempic intake. Individuals who took the drug for longer periods or at higher dosages might have a stronger case. Additionally, being unaware of the potential risks at the time of consumption is crucial, as many lawsuits claim that manufacturers failed to provide adequate warnings about the drug’s risks.
By consulting with an experienced attorney, potential plaintiffs can better understand their eligibility and the legal procedures involved in filing a claim in the Ozempic lawsuit MDL.
Filing an Ozempic lawsuit, like other personal injury or product liability claims, follows a series of steps to ensure the validity and strength of the claim. Here are the general steps to file a lawsuit:
Following these steps carefully can help ensure a robust legal case against the manufacturers of Ozempic. Working with a knowledgeable attorney will significantly increase your chances of a successful outcome, helping you secure the compensation needed for medical expenses, pain and suffering, and other related damages.
When Will Ozempic Lawsuit Be Settled? The timeline for Ozempic lawsuits to reach settlements is currently uncertain as cases are still in the early stages of litigation. The outcome of initial cases could set precedents for future settlements.
Settlements in Ozempic lawsuits may cover medical expenses, lost wages, pain and suffering, and other damages related to the adverse effects of the medication. As the litigation progresses, the resolution of early cases will provide insights into how future claims might be handled and what compensation plaintiffs might expect.
Get a Free Legal Case Review!
retired Judge Lawrence F. Stengel was appointed as the Special Discovery Master to oversee discovery disputes between the parties and third parties involved in the case.
In mid-August, the court issued Case Management Order No. 17, outlining the fee structure for the Ozempic MDL. A 9% fee from any gross monetary recovery, whether from settlement, judgment, or other forms of relief, will be allocated to the GLP-1 Fee Fund to compensate attorneys for their work benefiting all plaintiffs in the MDL.
Additionally, 2% of the gross recovery will go to the GLP-1 Expense Fund, covering litigation expenses such as discovery and expert analysis.
In an MDL, these fees are designed to distribute the costs of litigation fairly among all plaintiffs. Typically, the 2% expense fee impacts plaintiffs directly, while the 9% attorneys' fee is usually deducted from the contingency fees paid to plaintiffs’ lawyers.
In early August, a new lawsuit was filed in the MDL by a New Hampshire resident who was taking Ozempic from June 2022 to September 2023 and subsequently developed gastroparesis, a condition that paralyzes the stomach muscles, leading to severe digestive issues. The plaintiff claims that Novo Nordisk failed to adequately warn about the risks associated with Ozempic, resulting in her injuries and emotional distress. At the time, gastroparesis was not included in the Ozempic warning label.
Looking ahead, Judge Karen Spencer Marston has scheduled a "Science Day" for September 4, 2024. This unique proceeding will allow both parties to present an objective overview of the relevant medical and scientific issues related to GLP-1 RAs, helping the court better understand the science behind the claims. The presentations will focus strictly on scientific information, excluding individual cases or marketing practices, and are intended to be non-discoverable to encourage open discussion.
In the broader context of the MDL, the number of active cases has surged. From July to August 2024, the case count in MDL-3094, which includes various GLP-1 products like Ozempic, increased dramatically from 111 to 346—an over 200% jump in just one month.
A status conference was also held on August 8, 2024, where likely key issues were discussed, including the progress of electronic Plaintiff Fact Sheets (e-PFS), ongoing discovery developments, updates on stayed cases, and logistical planning for the upcoming Science Day.
The next status conference is scheduled for January 2025.
An Illinois man has filed a lawsuit against Novo Nordisk and Eli Lilly, alleging they failed to warn about the risks of their weight loss drugs, Ozempic and Mounjaro.
In October 2022, the plaintiff’s endocrinologist prescribed Ozempic for diabetes management. He used Ozempic until January 2023, then switched to Mounjaro for the same purpose.
On June 10, 2023, the plaintiff was hospitalized with chest discomfort that escalated to severe abdominal pain. A CT scan revealed abnormal thickening in the proximal jejunal small bowel and an internal hernia, indicating ischemia and bowel obstruction. The next day, he underwent surgery for ischemic bowel resection.
The lawsuit, filed in Illinois and set to be transferred to the MDL class action in Pennsylvania, seeks compensation for his injuries, medical expenses, pain, and suffering, which he attributes to the defendants’ negligence and deceptive practices.
There are 105 personal injury lawsuits for gastroparesis, ileus, and intestinal blockage or obstruction pending in MDL 3094 in the Eastern District of Pennsylvania.
The Judicial Panel on Multidistrict Litigation reassigned the Ozempic MDL to Judge Karen S. Marston.
Over 100 personal injury lawsuits against Novo Nordisk are consolidated in Ozempic MDL 3094 in the Eastern District of Pennsylvania. These cases focus on severe gastrointestinal issues, including gastroparesis and intestinal blockage.
The FDA has updated Ozempic’s warning label to include these risks.
Judge Gene E. K. Pratter, overseeing the MDL, passed away. This may affect the pace of litigation.
The Judicial Panel on Multidistrict Litigation consolidated 55 lawsuits into the Federal Multidistrict Litigation, expecting this number to rise significantly.
Reports indicate that Ozempic users are experiencing severe digestive issues, prompting legal actions against Novo Nordisk.
Ozempic has been linked to severe gastrointestinal issues, including gastroparesis and intestinal blockage.
Consult with your healthcare provider to discuss potential risks and consider alternative treatments if necessary.
Potential compensation may cover medical expenses, lost wages, pain and suffering, and other related damages.
The duration varies based on case specifics and legal strategies. Consulting with an attorney will provide a clearer timeline.
Our assistance makes locating a lawyer skilled in handling cases against pharmaceutical and drug companies like the Ozempic lawsuits easy. Simply complete our contact form, and upon submission, a member of our team will promptly contact you to link you with a seasoned attorney tailored to your case to assist you in the legal process.
Reach out to us today without delay to secure the expert legal support and Ozempic lawyer you need.
